Quincy Bioscience LLC and consumers alleging it duped them about the effectiveness of its Prevagen memory supplement asked a federal court in Florida to approve a nationwide class settlement that provides label changes and partial refunds to potentially 3 million people.
Plaintiffs say there’s no basis for the company’s claims that Prevagen can help memory or cognition. Prevagen’s active ingredient, a dietary protein first discovered in glowing jellyfish, is digested and transformed into amino acids before it can measurably affect the brain, they allege.
Quincy Bioscience agreed to an uncapped settlement that gives buyers back 30% of the manufacturer’s suggested ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.